Approved for use through 07/31/0206. OMB 0651-0

U.S. Patient and Tradematk Office, U.S. DEPARTMENT OF COMME!

U.S. Patient and Tradematk Office, U.S. DEPARTMENT OF COMME!

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unriess of contrars a valid OMB control num.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10521989		
Filing Date		2005-11-03		
First Named Inventor CHUI		NG, HESSON		
Art Unit		1615		
Examiner Name To Be		Assigned		
Attorney Docket Number		HANO.004		

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E)ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant Rele		Releva	es,Columns,Lines where evant Passages or Relevant ires Appear		
	1										
If you wisi	h to a	dd additional U.S. Publi				n information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code4	Publication	Name of Patente Applicant of cited Document	e or v	ages,Co	umns,Lines evant or Relevant	
	1	EP 0787 716 A1	EP			1997-06-08	Inomata et al.				С
	2	WO9917757	wo			1999-04-15	Lehne et al.				Г
	3	WO9817648	wo			1998-04-30	Ryder et al.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10521989		
Filing Date		2005-11-03		
First Named Inventor	CHU	CHUNG, HESSON		
Art Unit		1615		
Examiner Name	To Be	Assigned		
Attorney Docket Number		HANO-004		

	4	WO0213815	wo		2002-02-21	Woo et al.		-		
	5	WO03082199	wo		2003-10-09	Teather et al.				
If you wis	h to a	dd additional Foreign	Patent Document	citation	information pl	ease click the Add butto	n Add			
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţŝ			
	1 ECKER et al., "The Importance of a Nitropen Alors in Modulators of Multidrup Resistance" Molecular Pharmacology, 56:791-796 (1999)									
	2 KLOPMAN et al., "Quantitative Structure-Activity Relationship of Multidrug Resistance Reversal Agents" Molecular Pharmacology, 52:323-334 (1997)									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner	Signa	ature				Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Kind Cotes of USPTO Patent Documents at Invent USPTO.QDU/ or MPEP 901.04. Esters dolice that issued the document, by the Involvement and Inventor Section of the Section Patent Section Se

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10521989
Filing Date		2005-11-03
First Named Inventor	CHU	NG, HESSON
Art Unit		1615
Examiner Name	To Be	Assigned
Attorney Docket Number		HANO-004

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Karl Bozicevic

▼ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

28.807

Tomas or and origination			
Signature	/Karl Bozicevic/	Date (YYYY-MM-DD)	2007-03-26

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.